Latest News

In a cross-sectional analysis of more than 1700 participants, plasma CGRP concentrations did not distinguish individuals with migraine from healthy controls, suggesting limited utility as a standalone diagnostic biomarker.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is RNA-targeted therapeutics

The director of the Division of Neuroscience at IRCCS Istituto Ortopedico Rizzoli discussed why targeting shared biologic pathways, rather than individual mutations, may represent a promising therapeutic strategy for Charcot-Marie-Tooth disease. [WATCH TIME: 2 minutes]

An Oxford study found that current smokers with MOGAD had a 2.2-times higher annualized relapse rate than never smokers, while past smokers showed no elevated risk, supporting smoking cessation as a modifiable management target.

Ahead of the 2026 Alzheimer's Association International Conference, David Wolk, MD, discusses the meeting's biggest scientific themes, from plasma biomarkers and disease-modifying therapies to emerging technologies and evolving clinical practice.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending July 10, 2026.

Recent findings from a study of growth and nutritional status in primary ciliary dyskinesia revealed high rates of undernutrition, obesity, and vitamin D insufficiency across pediatric and adult populations.

Carol Rosen, MD, professor emerita of pediatrics at Case Western Reserve University School of Medicine, talked about the transformation of pediatric sleep medicine from a clinical curiosity to a core medical specialty at SLEEP 2026.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 20 minutes]

AbobotulinumtoxinA met its primary end point in both the E-BEOND and C-BEOND phase 3 trials, marking the first time a botulinum toxin has demonstrated statistically significant efficacy in episodic migraine prevention.

Fariha Abbasi-Feinberg, MD, FAASM, FAAN, newly installed president of the American Academy of Sleep Medicine and medical director of sleep medicine at Millennium Physician Group, shares her clinical and policy priorities for the year ahead and her vision for the future of sleep medicine.

Led by Na Tosha Gatson, MD, PhD, FAAN, director of the Center for Neuro-Oncology at the Indiana University Health Neurosciences and Cancer Institutes, this new column translates complex neuro-oncology topics into accessible, evidence-based insights.

TG Therapeutics has indicated it plans to submit a supplemental BLA to the FDA in the second half of 2026, seeking approval for the consolidated initiation regimen of ublituximab-xiiy.